1. Home
  2. APRE

as 04-02-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Founded: 2006 Country:
United States
United States
Employees: N/A City: DOYLESTOWN
Market Cap: 13.5M IPO Year: 2019
Target Price: $15.50 AVG Volume (30 days): 21.0K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.35 EPS Growth: N/A
52 Week Low/High: $1.85 - $6.70 Next Earning Date: 05-13-2025
Revenue: $1,502,581 Revenue Growth: 157.63%
Revenue Growth (this year): -38.91% Revenue Growth (next year): N/A

APRE Daily Stock ML Predictions

Share on Social Networks: